FDG and Beyond.

[1]  W. Oyen,et al.  18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy , 2013, The Journal of Nuclear Medicine.

[2]  Wim J. G. Oyen,et al.  Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  K. Haustermans,et al.  Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation? , 2013, Strahlentherapie und Onkologie.

[4]  T. Vercauteren,et al.  Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  C. Nanni,et al.  Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  B. Hoeben,et al.  18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome , 2013, The Journal of Nuclear Medicine.

[7]  Oliver Jäkel,et al.  Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET , 2013, Acta oncologica.

[8]  Dimitris Visvikis,et al.  Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET , 2013, Acta oncologica.

[9]  David Binns,et al.  The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  I. Steffen,et al.  Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[11]  I. Castiglioni,et al.  Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Riemer H. J. A. Slart,et al.  Value of 11C-methionine PET in imaging brain tumours and metastases , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  E. Hindié,et al.  Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Masayuki Matsuo,et al.  Clinical value of [¹¹C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors. , 2012, International journal of radiation oncology, biology, physics.

[15]  Philippe Lambin,et al.  Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.

[16]  Rodney J Hicks,et al.  The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. , 2012, Seminars in nuclear medicine.

[17]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  G. Fink,et al.  Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.

[19]  H. Hall,et al.  Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. , 2012, Nuclear medicine and biology.

[20]  Robert Jeraj,et al.  Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive? , 2012, The Lancet. Oncology.

[21]  S. Sauerland,et al.  Randomized Controlled Trials on PET: A Systematic Review of Topics, Design, and Quality , 2012, The Journal of Nuclear Medicine.

[22]  Xiaodong Wu,et al.  Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. , 2012, IEEE transactions on medical imaging.

[23]  H. Christofk,et al.  New aspects of the Warburg effect in cancer cell biology. , 2012, Seminars in cell & developmental biology.

[24]  K. Haustermans,et al.  OC-0050 DOES 11C-CHOLINE PET-CT CONTRIBUTE TO MULTIPARAMETRIC MR IMAGING FOR PROSTATE CANCER LOCALIZATION? , 2012 .

[25]  B. Seifert,et al.  Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  G. Semenza,et al.  Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.

[27]  Robert Jeraj,et al.  PET scans in radiotherapy planning of lung cancer. , 2012, Lung cancer.

[28]  F. Mottaghy,et al.  Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? , 2012, International journal of radiation oncology, biology, physics.

[29]  Fréderic Duprez,et al.  Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  W. Weber,et al.  New tracers beyond FDG in head and neck oncology. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[31]  J. Kaanders,et al.  FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[32]  R. Hicks,et al.  Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[33]  T. Beyer,et al.  Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. , 2011, International journal of radiation oncology, biology, physics.

[34]  Paul N. Span,et al.  Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  R. Wahl,et al.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. , 2011, Seminars in radiation oncology.

[36]  Vincent Gregoire,et al.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. , 2011, Seminars in radiation oncology.

[37]  R. T. Ten Haken,et al.  Functional and molecular image guidance in radiotherapy treatment planning optimization. , 2011, Seminars in radiation oncology.

[38]  Use of PET/CT for staging and radiation therapy planning in patients with non-small cell lung cancer. , 2010 .

[39]  Daniela Thorwarth,et al.  Physical radiotherapy treatment planning based on functional PET/CT data. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  Dirk De Ruysscher,et al.  PET scans in radiotherapy planning of lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  K. Haustermans,et al.  Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  Wolfgang A Weber,et al.  PET for radiation treatment planning of brain tumours. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  C. Haie-meder,et al.  Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  Luigi Gianolli,et al.  Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  Johan Bussink,et al.  Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  Rodney J Hicks,et al.  Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. , 2007, International journal of radiation oncology, biology, physics.

[47]  Tomas Kron,et al.  Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.

[48]  P. Grigsby.  PET/CT imaging to guide cervical cancer therapy. , 2009, Future oncology.

[49]  C. Dooms,et al.  Association Between 18F-Fluoro-2-Deoxy-d-Glucose Uptake Values and Tumor Vitality: Prognostic Value of Positron Emission Tomography in Early-Stage Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  D. Rubello,et al.  Clinical indications for Gallium-68 positron emission tomography imaging. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[52]  Tomio Inoue,et al.  Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  Jennifer E. Van Eyk,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[54]  Ursula Nestle,et al.  Biological imaging in radiation therapy: role of positron emission tomography , 2009, Physics in medicine and biology.

[55]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[56]  J. Barrio,et al.  FLT-PET Imaging of Radiation Responses in Murine Tumors , 2008, Molecular Imaging and Biology.

[57]  Andrea Schaefer,et al.  A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  Frederik Maes,et al.  Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG? , 2008, Acta oncologica.

[59]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[60]  M. Schwaiger,et al.  Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  Sigrid Stroobants,et al.  The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .

[62]  Y. Nishiyama,et al.  Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  M. Schwaiger,et al.  PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  Anne Bol,et al.  A gradient-based method for segmenting FDG-PET images: methodology and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  J. Ajani,et al.  Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models , 2006, Clinical Cancer Research.

[66]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[67]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[68]  E. Eisenhauer,et al.  RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.

[69]  Michael E Phelps,et al.  Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.

[70]  Ludwig G Strauss,et al.  Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of Nuclear Medicine.

[71]  Mark Muzi,et al.  Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  W. Martin,et al.  Metabolic Imaging with FDG: A Primer , 2004, Cancer journal.

[73]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[75]  L. Bettendorff,et al.  ATP‐driven, Na+‐independent inward Cl– pumping in neuroblastoma cells , 2002, Journal of neurochemistry.

[76]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[78]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[79]  S M Larson,et al.  Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.

[80]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Y Yonekura,et al.  In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  R. Iwata,et al.  Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  J. Foekens,et al.  High incidence of somatostatin receptors in human meningiomas: biochemical characterization. , 1986, The Journal of clinical endocrinology and metabolism.